Inhibition of gamma-endorphin generating endopeptidase activity of rat brain by peptides: structure activity relationship. 1985

J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach

gamma-Endorphin generating endopeptidase (gamma EGE) activity is an enzyme activity which converts beta-endorphin into gamma-endorphin and beta-endorphin-(18-31). The inhibitory potency on gamma EGE activity of neuropeptides and analogues or fragments of neuropeptides was tested. Dynorphin-(1-13) (IC50: 0.14 microM), human beta-endorphin-(1-31) (IC50: 15.5 microM), porcine ACTH-(1-39) (IC50: 6.3 microM), and substance P (IC50: 26 microM) had an inhibitory activity on gamma EGE activity. beta-Endorphin-(18-31) (IC50: 0.35 microM) but not gamma-endorphin potently inhibited gamma EGE activity. The IC50 of poly (Lys)40-60 was 0.8 microM. It is concluded that 1) gamma EGE activity is strongly inhibited by its product beta-endorphin-(18-31), 2) the enzyme is strongly inhibited by peptides with an aromatic amino acid at the NH2-terminal and/or basic amino acids in the COOH-terminal of the peptide chain.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
February 1985, Biochemical and biophysical research communications,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
August 1984, Analytical biochemistry,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
January 1986, Endocrinology,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
May 1980, Life sciences,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
January 1988, Neuroendocrinology,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
January 1980, Biochemical and biophysical research communications,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
June 2005, Journal of enzyme inhibition and medicinal chemistry,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
May 1982, Journal of neurochemistry,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
November 1976, Proceedings of the National Academy of Sciences of the United States of America,
J L Lebouille, and W H Visser, and R W Hendriks, and J W Van Nispen, and H M Greven, and J P Burbach
December 1995, European journal of pharmacology,
Copied contents to your clipboard!